Aging baby boomers are turning 65 years old at a pace of 10,000 per day, and that’s causing an increase in the diagnosis of common causes of vision loss, including age-related macular degeneration and diabetic macular edema. Patients with these conditions are increasingly being prescribed Regeneron Pharmaceuticals‘ (NASDAQ: REGN) Eylea, and as a result, Eylea’s selling at a $6 billion annualized clip globally.